Single-point accountability across regulatory strategy, device engineering, quality systems, and clinical validation workstreams, preventing coordination gaps.

Risk-adjusted project plans tied to regulatory submission deadlines, with dependencies mapped between drug product development, device validation, and technical documentation.

Strategic oversight of device manufacturers, contract labs, CDMOs, and packaging suppliers, ensuring specifications flow seamlessly between drug and device without costly rework cycles.

Design History File generation meeting FDA 21 CFR Part 4, Part 820 and ISO 13485, eliminating retrospective documentation archaeology.

Proactive identification of technical, regulatory, and supply chain risks with mitigation strategies that prevent timeline disruptions before they impact submissions.

Business-focused program dashboards translating technical progress into launch timeline certainty, regulatory pathway confidence, and other relevant metrics.